Cargando…
Design of two immunotoxins based rovalpituzumab antibody against DLL3 receptor; a promising potential opportunity
BACKGROUND AND PURPOSE: The lack of a new effective treatment for small cell lung cancer (SCLC) is an unresolved problem. Due to the new identification of delta-like ligand 3 (DLL3) and its high expression in SCLC patients, the use of DLL3 in target therapy can be effective. The use of bacterial tox...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wolters Kluwer - Medknow
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400466/ https://www.ncbi.nlm.nih.gov/pubmed/36034078 http://dx.doi.org/10.4103/1735-5362.350243 |